BPC-157
Body Protection Compound 157 — pentadecapeptide
A synthetic fifteen-amino-acid fragment derived from a protein found in human gastric juice. It carries one of the largest preclinical literatures of any compound in this space and almost no controlled human trial data.
- Category
- Repair & Recovery
- Half-life
- Approximately 4 hours
- Cycle length
- 4–6 weeks typical
- Level
- beginner
Overview
BPC-157 is a stable pentadecapeptide fragment of a larger protein isolated from human gastric juice. Because it survives stomach acid and appears to concentrate at sites of injury, early researchers were interested in its role in gut protection — hence the name. In the decades since, it became the default entry point for people exploring repair-focused peptides, and the compound that most other repair peptides are compared against.
How it works
The leading explanation is that BPC-157 acts on the VEGFR2–Akt–eNOS signalling pathway, encouraging angiogenesis — the formation of new blood vessels — at the site of injury. That improved local blood supply is thought to explain much of the accelerated tissue repair seen in animal models. It also appears to interact with the nitric oxide system and to modulate growth-factor receptor expression.
Reported benefits
- Faster resolution of induced tendon and ligament injuries in animal models
- Protection and repair of gut lining in ulcer and colitis models
- Soft-tissue and muscle injury recovery reports
- Reduced local inflammatory signalling in preclinical work
Reported benefits describe what the published literature and user reports suggest — not a promise of outcome for any individual.
Dosing reference
The range reported in the literature and in community practice is 250–500 mcg per day, usually split into one or two administrations. Subcutaneous injection close to the injury site is the most commonly described route; oral capsules are also widely sold.
Most described protocols run four to six weeks. Preclinical work used far higher relative doses in animals than the human figures quoted online, so treat these numbers as documentation of common practice rather than validated human dosing.
Most commonly reported: 250–500 mcg per day by subcutaneous injection, often split into one or two doses; oral capsules reported at 500–1,000 mcg per day for gut symptoms. Higher daily amounts are frequently described in injury threads, along with more injection-site complaints.
These figures are what people report using in public communities. They have not been studied, verified or checked against certificates of analysis, and they are not a recommendation, a prescription or a target to aim for.
Where the reported amounts come from
Amounts are reproduced for education only. Doses from trials cannot be assumed to suit anyone else, and community-reported amounts are frequently wrong. Self-administering unapproved compounds carries serious risk.
The research picture
The evidence base is dominated by rodent models. Tendon, ligament, muscle, gut and even nervous-system injuries have all shown accelerated healing under BPC-157 in animals, and the consistency across model types is notable. What is missing is the thing that matters most for human decisions: randomised, controlled trials in people. There is no published human safety database of meaningful size, which is why this page is more cautious than most of the internet.
Primary sources
Preclinical & non-clinical data
BPC-157's evidence base is almost entirely preclinical: rodent models of tendon, ligament, muscle, gut-lining and nerve injury, plus cell studies on fibroblast migration and new blood-vessel formation. Findings are consistent across several independent labs, which is genuinely informative — and it is still animal and cell data. No human pharmacokinetic study and no controlled human trial have been published, so absorption, distribution and human dose response are simply unknown.
Non-clinical data comes from cells and animals unless stated otherwise. It answers whether a compound is worth studying in people — not whether it is safe or effective in them.
What users report
Public reporting on BPC-157 is unusually large for a research peptide. Long-running threads in training, biohacking and peptide communities describe short courses — typically two to four weeks — for tendon and joint injuries, gut irritation and slow-healing skin. The recurring positives are faster improvement in tendon and gut symptoms and reduced need for painkillers; the recurring negatives are injection-site irritation, occasional lightheadedness and loose stools at higher amounts, and the suspicion that time alone did the repairing. Almost nobody in these accounts reports imaging or clinical follow-up, which is the honest limitation of the whole body of reports.
Where these reports come from
These are unverified personal accounts collected from public sources. They are not evidence of effectiveness or safety, they have not been independently checked, and they are not a recommendation to use anything described.
Possible side effects
- Injection-site irritation or redness
- Nausea reported anecdotally
- Dizziness and lightheadedness reported anecdotally
- Headache reported anecdotally
Safety notes
No formal human safety data exists. Because BPC-157 promotes angiogenesis, anyone with an active malignancy or a history of proliferative vascular disease should consider it off-limits until real human data exists — this is a theoretical concern rather than a documented one, but the mechanism is the reason for the caution. Do not combine with anticoagulants without clinical oversight.
Stacking
Most commonly paired with TB-500 in recovery protocols, on the reasoning that BPC-157 works locally at the injury while TB-500 redistributes systemically. Sequential rather than simultaneous introduction is the safer structure, so that any reaction can be attributed to one compound.
Related compounds
TB-500
Thymosin Beta-4 fragment
Repair & Recovery
Systemic repair signalling, rather than site-specific.
MGF
Mechano growth factor — IGF-1Ec splice variant
Repair & Recovery
A genuine exercise-repair signal with zero human injection data.